Image

Study of the No-touch Saphenous Vein Graft

Study of the No-touch Saphenous Vein Graft

Recruiting
25-70 years
All
Phase N/A

Powered by AI

Overview

Authors hypothesize that "no-touch" saphenous vein as I graft is superior over conventional "no-touch" saphenous vein as free graft in the incidence of graft patency.

Description

A multicenter single blind prospective randomized superiority study is conducted. Our hypothesis is that there is difference in the incidence of "no-touch" saphenous vein graft patency using it as the conventional free graft (group C) and I graft (group I) for myocardial revascularization more than 28%. If there is truly difference between groups, then total 106 patients for both groups are required to be 90% sure that the upper limit of a one-sided 95% confidence interval would reveal a difference in favour of the "no-touch" saphenous vein I graft of 28%. The blinding process is applied to a patient, who is informed about received harvesting method of saphenous vein, but don't know the type of the graft cofiguration. The study was approved by Institutional Review Board. Depending on a type of the procedure, the patients are divided into two groups: conventional free graft (group C) 53 patients and I graft (group I) 53 patients. Randomization is conducted befor operation by using accidental sampling.

Eligibility

Inclusion Criteria:

  • Patients with coronary artery disease requiring three-vessel myocardial revascularization
  • Patient consent to the study

Exclusion Criteria:

  • The diameter of the target arteries for conduits of the internal mammary arteries is less than 1 mm
  • Hemodynamically significant atherosclerosis of the subclavian arteries in the first segment
  • Stenosis of the right coronary artery less than 90%
  • Concomitant pathology requiring additional simultaneous surgical correction
  • Lack of IMA
  • COPD with FEV1 <60%
  • BMI >35
  • Prior heart surgery
  • Oncological diseases with a life expectancy of less than 5 years
  • ACS
  • CKD stage 4 and higher
  • The diameter of the SVG is less than 2 mm or its varicose expansion is more than 6 mm
  • CLTI IIb and more
  • Atherosclerosis of the brachiocephalic artery more than 50%

Study details
    Coronary Artery Disease
    Coronary Artery Stenosis
    Graft Failure
    Cardiac Ischemia
    Surgery

NCT05757947

Meshalkin Research Institute of Pathology of Circulation

15 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.